ERBB2 and cancer: Previous research in our laboratory demonstrated that pharmacological inhibition of FASN activity markedly reduces HER2 oncogene expression in cancer cells.11, 12, 13 RNA interference (RNAi)-mediated silencing of FASN also represses HER2 expression.